Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Nove Mesto Nad Vahom – page 3

246 clinical trials in Nove Mesto Nad Vahom, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Nove Mesto Nad Vahom at a glance
246
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

246 trials in Nove Mesto Nad Vahom

Open in trial search

Study of Orforglipron in Overweight Adults at Risk of Developing Obesity‑Related Complications or Class 1 Obesity

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Efficacy, Safety, and Tolerability of NBI-1065890 in Adults with Tardive Dyskinesia

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:NBI-1065890
  • Sponsor:Neurocrine Biosciences Inc.

Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

InvestigationalNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Amgen Inc.

A Phase 3 Study of Enpatoran to Treat Active Cutaneous Lupus in Patients With or Without Systemic Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Enpatoran hemihydrate
  • Sponsor:Merck Healthcare KGaA

Efficacy and safety of sarilumab plus prednisone versus prednisone alone in adults with early polymyalgia rheumatica

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

Asthma

Recruiting

Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

Registered drug
Countries:SlovakiaSlovakia
  • Participants:0–17 years
  • Substances:Indacaterol Acetate
  • Sponsor:Novartis Pharma AG

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Dyslipidaemia

Recruiting

Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

Registered drug
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid
  • Sponsor:A. Menarini International Licensing S.A.

Obesity+2

Recruiting

Study of the efficacy and safety of Eloralintide in adults with knee osteoarthritis and overweight or obesity

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

A study to compare the efficacy and safety of AVT29 and aflibercept in patients with diabetic macular edema

Registered drugNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Alvotech Swiss AG

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Nove Mesto Nad Vahom

What the registry says about research in the country

01 Cardiovascular Diseases

Clinical trial activity in Stara Tura is focused on cardiovascular diseases, with studies involving adults who have atherosclerotic cardiovascular disease and chronic kidney disease. The research is aimed at better understanding how new treatments may lower the risk of serious heart-related events.

  • Testing new approaches for atherosclerotic cardiovascular disease and chronic kidney disease
  • Studying established cardiovascular disease and high cardiovascular risk
  • Evaluating treatment options for hypertension

These trials are designed to assess whether new therapies can improve prevention of major cardiovascular complications and support better long-term outcomes.

02 Cardiometabolic and Kidney-Related Risk

The local research portfolio also addresses overlapping cardiovascular and kidney-related risk, reflecting the close connection between blood vessel disease, blood pressure control, and renal health. This work helps evaluate whether emerging treatments can reduce events such as heart attack, stroke, or heart failure.

  • Improving outcomes in people with high cardiovascular risk
  • Exploring prevention strategies for heart failure and related complications
  • Supporting better control of hypertension in high-risk patients

In this setting, researchers are focusing on whether new therapies can offer stronger protection than standard care for patients most vulnerable to major cardiovascular events.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.